Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Favipiravir for hospitalized patients with COVID-19
IRCT20201028049175N1Phase 3Completed
- Sponsor
- Arak University of Medical Sciences
- Start
- Nov 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in coronavirus disease 2019 (COVID-19) comparing Favipiravir with Placebo control (2 arms). Primary endpoint: Severity of COVID-19. Started Nov 2020; status: completed.
02
Drugs
favipiravir
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on IRCT20201028049175N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20201028049175N1.